Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma, T-Cell, Cutaneous 4Leukemia-Lymphoma, Adult T-Cell 4Sezary Syndrome 3Neoplasms 3Mycosis Fungoides 3Carcinoma 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Hematologic Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Injections 25Carboplatin 17Docetaxel 14pembrolizumab 12Paclitaxel 11Bevacizumab 9durvalumab 8Cisplatin 8Nivolumab 6Fluorouracil 6trifluridine tipiracil drug combination 5tislelizumab 5linifanib 5Pemetrexed 5Oxaliplatin 5Leucovorin 5zimberelimab 4toripalimab 4talazoparib 4olaparib 4Itraconazole 4Irinotecan 4Gemcitabine 4Capecitabine 4tremelimumab 3sotorasib 3sintilimab 3fludarabine 3depatuxizumab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumors × mogamulizumab × Clear all
NCT02301130 2024-04-25

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Kyowa Kirin Co., Ltd.

Phase 1 Completed
64 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡